ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 117 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.25 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $343,000 | +36.1% | 18,132 | -15.4% | 0.00% | – |
Q2 2019 | $252,000 | +20.6% | 21,428 | +39.7% | 0.00% | – |
Q1 2019 | $209,000 | +23.7% | 15,339 | -7.3% | 0.00% | – |
Q4 2018 | $169,000 | -37.2% | 16,546 | +2.6% | 0.00% | – |
Q3 2018 | $269,000 | +5.5% | 16,123 | -0.0% | 0.00% | – |
Q2 2018 | $255,000 | +27.5% | 16,131 | +2.6% | 0.00% | – |
Q1 2018 | $200,000 | -52.6% | 15,717 | -57.4% | 0.00% | – |
Q4 2017 | $422,000 | +76.6% | 36,881 | +89.1% | 0.00% | – |
Q3 2017 | $239,000 | +408.5% | 19,505 | +370.8% | 0.00% | – |
Q2 2017 | $47,000 | -59.8% | 4,143 | -26.0% | 0.00% | – |
Q1 2017 | $117,000 | +2825.0% | 5,602 | +3047.2% | 0.00% | – |
Q4 2016 | $4,000 | -33.3% | 178 | 0.0% | 0.00% | – |
Q3 2016 | $6,000 | +50.0% | 178 | 0.0% | 0.00% | – |
Q2 2016 | $4,000 | -50.0% | 178 | -45.1% | 0.00% | – |
Q1 2016 | $8,000 | +14.3% | 324 | +54.3% | 0.00% | – |
Q4 2015 | $7,000 | 0.0% | 210 | 0.0% | 0.00% | – |
Q3 2015 | $7,000 | – | 210 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |